Ticker Launch
Sign inTry it free

Reverse merger · Completed · DWTX

Pharmagesic (Holdings) Inc. (Wex Pharmaceuticals)

Reverse merger with Virios Therapeutics, Inc. (VIRI)

Pharmagesic (Holdings) Inc. (Wex Pharmaceuticals) merged into Virios Therapeutics, Inc. (VIRI), a development-stage biotech (IMC-1 fibromyalgia, IMC-2 Long-COVID), in a reverse merger that takes the private company public. The agreement was signed and the deal closed on the same day, Oct 7, 2024. The combined company trades as Dogwood Therapeutics, Inc. (DWTX) on Nasdaq.

Dogwood Therapeutics, Inc. develops non-opioid pain treatments, including Halneuron, a NaV1.7 inhibitor in Phase 2b for chemotherapy-induced neuropathic pain, alongside IMC-1 for fibromyalgia and IMC-2 for Long-COVID.

Status
Completed
Private company
Pharmagesic (Holdings) Inc. (Wex Pharmaceuticals)
Public company
Virios Therapeutics, Inc. (VIRI)
Public company business before
development-stage biotech (IMC-1 fibromyalgia, IMC-2 Long-COVID)
Announced
Signed and closed the same day
Closed
Oct 7, 2024
Combined company
Dogwood Therapeutics, Inc. (DWTX)
Exchange
Nasdaq
Sector
Biotech & pharma

More on this deal for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other completed reverse mergers